PHARMACEUTICAL COMBINATIONS Russian patent published in 2018 - IPC A61K45/06 A61K31/404 A61K31/4184 A61K31/517 A61P35/00 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: invention relates to the pharmaceutical industry, in particular to a combination containing a protein kinase C (PKC) inhibitor compound, which is 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]-1H-pyrrole-2,5-dione or a pharmaceutically acceptable salt thereof, and a mitogen-activated protein kinase (MEK) inhibitor compound, which is 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid 2-hydroxyethoxy-amide, or a pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for use in the treatment of a proliferative disease. Use of a pharmaceutical combination in the preparation of a medicament for the treatment of a proliferative disease. Use of a pharmaceutical combination in the manufacture of a medicinal agent for the treatment of melanoma. Method of using the pharmaceutical combination to treat a patient suffering from a proliferative disease. Combined formulation for use in the treatment of a proliferative disease, comprising (a) one or more standard dosage forms of a PKC inhibitor compound, which is 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]-1H-pyrrole-2,5-dione or a pharmaceutically acceptable salt thereof, and (b) one or more standard dosage forms of the MEK inhibitor compound, which is 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzimidazole-5-carboxylic acid 2-hydroxyethoxy-amide.

EFFECT: pharmaceutical combination has a synergistic interaction with respect to strong inhibition of cell proliferation.

34 cl, 6 dwg, 1 tbl, 7 ex